Bausch Health’s Campaign Aims to Educate on Xifaxan for Hepatic Encephalopathy

Bausch Health Companies Inc. has launched a new "I Wish I Knew" campaign through its gastroenterology branch, Salix Pharmaceuticals. The campaign's goal is to educate and empower individuals about Xifaxan (rifaximin), the only FDA-approved medication to reduce the risk of overt hepatic encephalopathy (OHE) recurrence in adults. OHE, a complication arising from cirrhosis, can severely impact cognitive function due to toxins affecting the brain.

Salix's campaign highlights real patient experiences, bringing authentic stories to the forefront. A key feature is a 60-second segment narrating a woman’s journey with OHE symptoms and Xifaxan treatment. The initiative underscores Salix’s commitment to patient education and advocacy in collaboration with groups like the Global Liver Institute.

Salix aims to inform about the progression from chronic liver disease to cirrhosis and the implications on the brain. The company emphasizes the potential for managing recurrent OHE episodes and providing quicker care access.